282 related articles for article (PubMed ID: 22679301)
1. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
de Jong PH; Hazes JM; Barendregt PJ; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
Ann Rheum Dis; 2013 Jan; 72(1):72-8. PubMed ID: 22679301
[TBL] [Abstract][Full Text] [Related]
2. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
de Jong PH; Hazes JM; Han HK; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; van Schaeybroeck B; de Sonnaville PB; van Krugten MV; Luime JJ; Weel AE
Ann Rheum Dis; 2014 Jul; 73(7):1331-9. PubMed ID: 24788619
[TBL] [Abstract][Full Text] [Related]
3. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
5. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
6. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
7. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
8. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
12. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
13. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
[TBL] [Abstract][Full Text] [Related]
14. Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study.
de Jong PH; Quax RA; Huisman M; Gerards AH; Feelders RA; de Sonnaville PB; Luime JJ; Weel AE; Hazes JM
Ann Rheum Dis; 2013 Oct; 72(10):1659-63. PubMed ID: 23117243
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
16. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
[TBL] [Abstract][Full Text] [Related]
17. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy in rheumatoid arthritis].
Johnsen V; Førre Ø; Haga HJ; Kvien TK; Mikkelsen K; Nordvåg BY; Rødevand E
Tidsskr Nor Laegeforen; 2003 May; 123(11):1511-3. PubMed ID: 12822010
[TBL] [Abstract][Full Text] [Related]
19. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
20. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
